Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney function and olpasiran: a safety check

NCT ID NCT05489614

First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 21 times

Summary

This study tested a single dose of the drug olpasiran in 33 adults with normal kidney function or varying degrees of kidney impairment. The goal was to see how the body processes the drug and to check for safety. Results help doctors understand dosing for patients with kidney issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Advanced Pharma CR, LLC

    Miami, Florida, 33147-4040, United States

  • CRSCA HC LLC, dba Creekside Post Acute

    Yucaipa, California, 92399, United States

  • Clinical Pharmacology Of Miami, LLC

    Miami, Florida, 33014, United States

  • Inland Empire Clinical Trials, LLC

    Rialto, California, 92377-4697, United States

  • Nucleus Network - Minneapolis

    Saint Paul, Minnesota, 55114, United States

  • Orlando Clinical Research Center

    Orlando, Florida, 32809, United States

Conditions

Explore the condition pages connected to this study.